Komal Jhaveri, MD, Memorial Sloan Kettering Cancer Center and lead author of the EMBER-3 trial, as she discusses the significance of this approval, its impact on the treatment…
Sung-Bae Kim, MD, PhD, Asan Medical Center, Seoul, South Korea, reports on results from the East Asian subgroup of the Phase 3 EMBER‑3 trial, showing that in patients…
NEW YORK (Reuters Health) – Laparoscopic surgery is as efficient as open surgery for rectal cancer, according to results of a randomized trial. Dr. Juan Lujan and colleagues…
NEW YORK (Reuters Health) – The median survival of patients with peritoneal breast cancer metastasis is “surprisingly poor,” with only a small minority surviving longer than 6 months,…
NEW YORK (Reuters Health) – Because of their ability to prevent, reduce, and delay skeletal complications with multiple myeloma, bisphosphonates are an essential component of treatment for this…
NEW YORK (Reuters Health) – Women treated for grade 1 breast cancer have a low risk of locoregional recurrence and contralateral breast cancer, results of a study indicate.…
NEW YORK (Reuters Health) – Disease-free survival with breast cancer is not improved by adding tamoxifen therapy either before or after treatment with letrozole, according to a report…
Miguel Materin, MD, Assistant Professor of Ophthalmology, Director of Ocular Oncology Section Yale University School of Medicine, describes uveal melanoma, a rare cancer but the most common cause…
NEW YORK (Reuters Health) – The tyrosine kinase inhibitor gefitinib is more effective than standard therapy with carboplatin-paclitaxel for lung adenocarcinomas with mutations in the epidermal growth factor…
NEW YORK (Reuters Health) – Roughly 56% of melanomas detected in general dermatology practice are found through full-body skin examinations (FBSE), not as the result of patient complaint,…
NEW YORK (Reuters Health) – Use of 18F-FDG PET imaging can reduce the rate of futile laparotomies in patients with colorectal liver metastases from 45% to 28%, according…
NEW YORK (Reuters Health) – A meta-analysis of trial data suggests that erythropoietin can be safely used to treat anemia in patients with chronic heart failure and may…
